<HashMap><database>biostudies-other</database><scores/><additional><submitter>Craig EL</submitter><funding>NIDA NIH HHS</funding><funding>Canadian Institutes of Health Research</funding><pagination>1447-55</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4152873</full_dataset_link><abstract>Several behavioral studies report that adolescent rats display a preference for nicotine compared with adults. However, age-related pharmacokinetic differences may confound the interpretation of these findings. Thus, differences in pharmacokinetic analyses of nicotine were investigated. Nicotine was administered via acute s.c. (1.0 mg base/kg) or i.v. (0.2 mg base/kg) injection to early adolescent (EA; postnatal day 25) and adult (AD; postnatal day 71) male Wistar rats. Nicotine and its primary metabolite, cotinine, and additional metabolites nornicotine, nicotine-1'-N-oxide, trans-3'-hydroxycotinine, and norcotinine were sampled from 10 minutes to 8 hours (plasma) and 2 to 8 hours (brain) post nicotine and analyzed by liquid chromatography-tandem mass spectrometry. Following s.c. nicotine, the EA cohort had lower levels of plasma nicotine, cotinine, and nicotine-1'-N-oxide at multiple time points, resulting in a lower area under the plasma concentration-time curve (AUC) for nicotine (P &lt; 0.001), cotinine (P &lt; 0.01), and nicotine-1'-N-oxide (P &lt; 0.001). Brain levels were also lower for these compounds. In contrast, the EA cohort had higher plasma and brain AUCs (P &lt; 0.001) for the minor metabolite nornicotine. Brain-to-plasma ratios varied for nicotine and its metabolites, and by age. Following i.v. nicotine administration, similar age-related differences were observed, and this route allowed detection of a 1.6-fold-larger volume of distribution and 2-fold higher plasma clearance in the EA cohort compared with the AD cohort. Thus, unlike in humans, there are substantial age differences in nicotine pharmacokinetics such that for a given nicotine dose, adolescent rats will have lower plasma and brain nicotine compared with adults, suggesting that this should be considered when interpreting animal model data.</abstract><repository>biostudies-other</repository><data_source>Europe PMC</data_source><omics_type>Unknown</omics_type><volume>42(9)</volume><journal>Drug metabolism and disposition: the biological fate of chemicals</journal><pmcid>PMC4152873</pmcid><funding_grant_id>MOP97751</funding_grant_id><funding_grant_id>U01 DA020830</funding_grant_id><funding_grant_id>U01-DA020830</funding_grant_id><pubmed_authors>Craig EL</pubmed_authors><pubmed_authors>Zhao B</pubmed_authors><pubmed_authors>Novalen M</pubmed_authors><pubmed_authors>Cui JZ</pubmed_authors><pubmed_authors>Miksys S</pubmed_authors><pubmed_authors>Tyndale RF</pubmed_authors></additional><is_claimable>false</is_claimable><name>Nicotine pharmacokinetics in rats is altered as a function of age, impacting the interpretation of animal model data.</name><description>Several behavioral studies report that adolescent rats display a preference for nicotine compared with adults. However, age-related pharmacokinetic differences may confound the interpretation of these findings. Thus, differences in pharmacokinetic analyses of nicotine were investigated. Nicotine was administered via acute s.c. (1.0 mg base/kg) or i.v. (0.2 mg base/kg) injection to early adolescent (EA; postnatal day 25) and adult (AD; postnatal day 71) male Wistar rats. Nicotine and its primary metabolite, cotinine, and additional metabolites nornicotine, nicotine-1'-N-oxide, trans-3'-hydroxycotinine, and norcotinine were sampled from 10 minutes to 8 hours (plasma) and 2 to 8 hours (brain) post nicotine and analyzed by liquid chromatography-tandem mass spectrometry. Following s.c. nicotine, the EA cohort had lower levels of plasma nicotine, cotinine, and nicotine-1'-N-oxide at multiple time points, resulting in a lower area under the plasma concentration-time curve (AUC) for nicotine (P &lt; 0.001), cotinine (P &lt; 0.01), and nicotine-1'-N-oxide (P &lt; 0.001). Brain levels were also lower for these compounds. In contrast, the EA cohort had higher plasma and brain AUCs (P &lt; 0.001) for the minor metabolite nornicotine. Brain-to-plasma ratios varied for nicotine and its metabolites, and by age. Following i.v. nicotine administration, similar age-related differences were observed, and this route allowed detection of a 1.6-fold-larger volume of distribution and 2-fold higher plasma clearance in the EA cohort compared with the AD cohort. Thus, unlike in humans, there are substantial age differences in nicotine pharmacokinetics such that for a given nicotine dose, adolescent rats will have lower plasma and brain nicotine compared with adults, suggesting that this should be considered when interpreting animal model data.</description><dates><release>2014-01-01T00:00:00Z</release><publication>2014 Sep</publication><modification>2019-03-27T01:35:05Z</modification><creation>2019-03-27T01:35:05Z</creation></dates><accession>S-EPMC4152873</accession><cross_references><pubmed>24980255</pubmed><doi>10.1124/dmd.114.058719 </doi></cross_references></HashMap>